These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 25443247)

  • 1. Optimal anticoagulation duration of unfractionated and low molecular weight heparin in non-ST elevation acute coronary syndrome: a systematic review of the literature.
    Riaz IB; Asawaeer M; Riaz H; Gabriel WM; Tabash IK; Bilal J; Alpert JS
    Int J Cardiol; 2014 Dec; 177(2):461-6. PubMed ID: 25443247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of anticoagulation in acute coronary syndromes.
    Latour-Pérez J; de-Miguel-Balsa E
    Pharmacoeconomics; 2012 Apr; 30(4):303-21. PubMed ID: 22409291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin versus placebo for non-ST elevation acute coronary syndromes.
    Andrade-Castellanos CA; Colunga-Lozano LE; Delgado-Figueroa N; Magee K
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD003462. PubMed ID: 24972265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of low molecular weight heparin with unfractionated heparin during percutaneous coronary interventions: a meta-analysis.
    Kodumuri V; Adigopula S; Singh P; Swaminathan P; Arora R; Khosla S
    Am J Ther; 2011 May; 18(3):180-9. PubMed ID: 20027109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review].
    Husted SE; Nielsen HK
    Ugeskr Laeger; 2010 Sep; 172(37):2522-6. PubMed ID: 20836961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors.
    Bangalore S; Toklu B; Kotwal A; Volodarskiy A; Sharma S; Kirtane AJ; Feit F
    BMJ; 2014 Nov; 349():g6419. PubMed ID: 25389143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparin versus placebo for acute coronary syndromes.
    Magee KD; Campbell SG; Moher D; Rowe BH
    Cochrane Database Syst Rev; 2008 Apr; (2):CD003462. PubMed ID: 18425889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis.
    Lazrak HH; René É; Elftouh N; Leblanc M; Lafrance JP
    BMC Nephrol; 2017 Jun; 18(1):187. PubMed ID: 28592259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: a systematic review and meta-analysis.
    Galli M; Andreotti F; D'Amario D; Vergallo R; Vescovo GM; Giraldi L; Migliaro S; Ameri P; Porto I; Crea F
    Eur Heart J Cardiovasc Pharmacother; 2020 Jan; 6(1):43-56. PubMed ID: 31350546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review].
    Husted SE; Nielsen HK
    Ugeskr Laeger; 2010 Oct; 172(42):2888-91. PubMed ID: 21040659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors.
    Lepor NE
    Rev Cardiovasc Med; 2007; 8 Suppl 3():S9-17. PubMed ID: 17917621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of low-molecular-weight heparin in invasive management of non-ST-elevation acute coronary syndromes.
    Moser LR; Kalus JS
    Ann Pharmacother; 2004 Dec; 38(12):2094-104. PubMed ID: 15536140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-molecular-weight heparins : mechanisms, trials, and role in contemporary interventional medicine.
    Canales JF; Ferguson JJ
    Am J Cardiovasc Drugs; 2008; 8(1):15-25. PubMed ID: 18303934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial.
    Steg PG; Mehta SR; Pollack CV; Bode C; Cohen M; French WJ; Hoekstra J; Rao SV; Ruzyllo W; Ruiz-Nodar JM; Sabaté M; Widimsky P; Kiss RG; Navarro Estrada JL; Hod H; Kerkar P; Guneri S; Sezer M; Ruda M; Nicolau JC; Cavallini C; Ebrahim I; Petrov I; Kim JH; Jeong MH; Ramos Lopez GA; Laanmets P; Kovar F; Gaudin C; Fanouillere KC; Minini P; Hoffman EB; Moryusef A; Wiviott SD; Sabatine MS;
    JAMA; 2013 Sep; 310(11):1145-55. PubMed ID: 23995608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of unfractionated heparin and a low-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction.
    Wang XK; Zhang Y; Yang CM; Wang Y; Liu GY
    Clin Drug Investig; 2006; 26(6):341-9. PubMed ID: 17163268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.
    Sobieraj DM; Coleman CI; Tongbram V; Chen W; Colby J; Lee S; Kluger J; Makanji S; Ashaye A; White CM
    Pharmacotherapy; 2012 Sep; 32(9):799-808. PubMed ID: 22744711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III).
    Waksman R; Bertrand O; Driesman M; Gruberg L; Rossi J; Mehta S; Swymelar S; Dvir D; Xue Z; Torguson R
    J Interv Cardiol; 2013 Apr; 26(2):107-13. PubMed ID: 23240743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of antithrombotics for acute coronary syndromes in the emergency department: considerations and impact.
    Mukherjee D; Eagle KA
    Prog Cardiovasc Dis; 2007; 50(3):167-80. PubMed ID: 17976502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes.
    Califf RM; Petersen JL; Hasselblad V; Mahaffey KW; Ferguson JJ
    Am Heart J; 2005 Apr; 149(4 Suppl):S91-9. PubMed ID: 16124953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux.
    Steg PG; Mehta S; Jolly S; Xavier D; Rupprecht HJ; Lopez-Sendon JL; Chrolavicius S; Rao SV; Granger CB; Pogue J; Laing S; Yusuf S
    Am Heart J; 2010 Dec; 160(6):1029-34, 1034.e1. PubMed ID: 21146654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.